[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation
暂无分享,去创建一个
Peter R. Martin | C. Jack | R. Petersen | B. Boeve | M. Senjem | D. Knopman | V. Lowe | J. Whitwell | K. Josephs | K. Josephs | F. Ali | J. Whitwell | P. Martin | Farwa Ali | D. Knopman
[1] Hanna Cho,et al. Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation , 2018, The Journal of Nuclear Medicine.
[2] Keith A. Johnson,et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[3] Luca Passamonti,et al. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[4] Hanna Cho,et al. 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome , 2017, Neurology.
[5] P. Svenningsson,et al. In vivo retention of 18F-AV-1451 in corticobasal syndrome , 2017, Neurology.
[6] R. Thangavel,et al. Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..
[7] D. Holtzman,et al. Glial contributions to neurodegeneration in tauopathies , 2017, Molecular Neurodegeneration.
[8] Keith A. Johnson,et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.
[9] David T. Jones,et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.
[10] A. Takeda,et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET , 2016, Neurology.
[11] J. Trojanowski,et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[12] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[13] C. Jack,et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[14] Hanna Cho,et al. Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.
[15] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[16] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[17] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[18] Robert I. Reid,et al. The evolution of primary progressive apraxia of speech. , 2014, Brain : a journal of neurology.
[19] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[20] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[21] C. Jack,et al. Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech , 2012, Brain : a journal of neurology.
[22] J. Trojanowski,et al. Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.
[23] C. Jack,et al. Imaging correlates of pathology in corticobasal syndrome , 2010, Neurology.
[24] F. Pasquier,et al. Prediction of pathology in primary progressive language and speech disorders , 2010, Neurology.
[25] J. Hodges,et al. Is the pathology of corticobasal syndrome predictable in life? , 2009, Movement disorders : official journal of the Movement Disorder Society.
[26] R. Petersen,et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome , 2009, Movement disorders : official journal of the Movement Disorder Society.
[27] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[28] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[29] Jennifer L. Whitwell,et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.
[30] J. Duffy. Apraxia of speech in degenerative neurologic disease , 2006 .
[31] Joseph James Duffy,et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia , 2005, Neurocase.
[32] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[33] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[34] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[35] I Litvan,et al. The FAB: A frontal assessment battery at bedside , 2000, Neurology.
[36] R. Petersen,et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.
[37] A. Aronson,et al. Motor Speech Disorders , 2014 .
[38] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[39] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[40] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.